Tissue Regenix gains approval for first product

Tissue Regenix today announced that it had received European CE Marking for its dCELL vascular patch.

The dCELL vascular patch is a sterile, non-cellular biological "scaffold" which is intended to be permanently implanted into the human body for vascular repair.

Tissue's technology, dCELL, removes cells from human and animal body parts to create a scaffold which can be used to replace worn out or diseased body parts, without the need for anti-rejection drugs.

Tissue Regenix, which joined AIM (the Alternative Investment Market) in June via a reverse takeover of Oxeco, will manufacture the dCELL vascular patch at its York facility.

Tissue Regenix will now be simultaneously working towards receiving FDA approval for the US.

The next product on which Tissue Regenix intends to focus is the dCELL meniscus, which helps to repair knees.

John Samuel, Tissue Regenix executive chairman, said: "The granting of a European CE mark for the dCELL vascular patch, our first product approved for launch, is an historic moment for Tissue Regenix.

"As well as providing access to some of the world's largest medical devices markets, today's announcement acts as a validation of our dCELL technology platform."